-
In a survey of consecutive myeloma patients from the Mayo Clinic on hypothetical constructs with varying expectations regarding overall survival benefit, toxicity, and financial burden, it was found that the majority of patients would not choose maintenance if toxicity was more than just mild and overall survival benefit was less than 1 year.
-
A previously reported, industry-sponsored phase 3 trial showed improvements in progression-free survival, objective response, and a non-significant trend toward increased overall survival with panitumumab-FOLFIRI vs FOLFIRI alone for second-line wild-type KRAS metastatic colorectal cancer.
-
Using the SEER database, this report examined 1926 patients aged ≥ 70 years who were diagnosed with limited-stage small cell lung cancer between 1988 and 1997.
-
Long-term complications, particularly secondary cancers, were significantly more common in patients receiving whole pelvic radiation (vs brachytherapy alone) for early-stage endometrial cancer.
-
For patients with BRCA-associated breast cancer, it had been previously demonstrated that a second breast cancer occurs in approximately one-third of patients by 15 years after diagnosis, and that this risk was reduced significantly by contralateral mastectomy.
-
Bevacizumab added to chemotherapy, particularly paclitaxel and cisplatin, was efficacious in all response outcomes (objective response, progression-free survival, and overall survival) without diminution in quality of life or unacceptable toxicity.
-
In a well-controlled retrospective analysis of patients who presented with metastatic colorectal cancer, primary tumor resection was associated with improved overall survival.
-
In a multicenter, randomized, double-blind, placebo-controlled clinical trial of bevacizumab added to standard temozolomide and radiation therapy for patients with glioblastoma multiforme, progression-free survival but not overall survival was enhanced.
-
There has been some controversy on the role of taxanes in combination with platinum for the treatment of ovarian cancer. In the current report, patients who relapsed after a disease-free interval of 6 months or more were randomized in 2 large, multicenter trials conducted in Europe to receive either platinum (or typical platinum-based regimens) or paclitaxel plus platinum.
-
Women who survive breast cancer may be at a lower risk of developing coronary artery disease compared with women without a history of breast cancer.
